HealthCast: Experimental drug daraxonrasib gives some pancreatic patients hope

Experimental drug daraxonrasib shows promise in treating pancreatic cancer, with clinical trial participants experiencing extended survival times. Former U.S. Senator Ben Sasse, part of the trial, reported significant tumor reduction. The drug targets RAS gene mutations common in pancreatic cancer and is under FDA priority review.